{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:09:29Z","timestamp":1788419369362,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Soochow University Start-up Fund","award":["ND2022A03"],"award-info":[{"award-number":["ND2022A03"]}]},{"name":"the Soochow University Start-up Fund","award":["ND2023B02"],"award-info":[{"award-number":["ND2023B02"]}]},{"name":"the project of Suzhou Science and Technology","award":["SKY2022159"],"award-info":[{"award-number":["SKY2022159"]}]},{"name":"the Discipline Construction Program of the Second Affiliated Hospital of Soochow University","award":["HKTJ-HRC2021004"],"award-info":[{"award-number":["HKTJ-HRC2021004"]}]},{"name":"Jiangsu Provincial Medical Key Discipline","award":["ZDXK202217"],"award-info":[{"award-number":["ZDXK202217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Overactive bladder (OAB) and dyskinesia are frequent complications in patients with Parkinson\u2019s disease (PD). However, the correlation between OAB and dyskinesia has been insufficiently explored. The purpose of this study was to examine the relationship between dyskinesia, OAB, and clinical characteristics among individuals with PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>1338 PD patients were included in the present study. Demographic features were compared between patients with or without dyskinesia and OAB symptoms. Logistic regression was conducted on dyskinesia to screen clinically relevant factors. Overactive Bladder Symptom Score (OABSS) was further used to stratify the association between the severity of OAB and the occurrence of dyskinesia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study indicates that both dyskinesia and OAB are significantly related to disease severity and cognitive status. PD patients with dyskinesia and OAB having higher UPDRS scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), H-Y scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), NMSQ (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and MoCA scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and lower MMSE scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) are identified. The multivariate logistic regression confirms that disease duration (<jats:italic>p<\/jats:italic>\u2009=\u20090.041), LEDD (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), UPDRSII (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MoCA (<jats:italic>p<\/jats:italic>\u2009=\u20090.024), urgency (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), frequency (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and nocturia (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) are independent risk factors for dyskinesia. Trend analysis indicates that the risk of dyskinesia significantly increases when patients exhibit moderate to severe OAB symptoms (OABSS\u2009&gt;\u20095) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). No significant interactions were found between OABSS and age, gender, disease duration, LEDD, and NMSQ scores in different subgroups, indicating that dyskinesia is more pronounced in patients with OABSS\u2009&gt;\u20095.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study provides compelling evidence supporting the strong correlation between OAB and dyskinesia in PD patients, emphasizing the presence of shared pathogenic mechanisms between these two conditions. Our findings underscore the importance of considering both OAB and dyskinesia in the clinical management of PD, investigating the intricate connections between OAB and dyskinesia could unveil valuable insights into the complex pathophysiology of PD and potentially identify novel therapeutic targets for more effective PD treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03578-3","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T06:07:49Z","timestamp":1710223669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson\u2019s disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Hong","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"3578_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1474-4422(15)00362-2","volume":"15","author":"N Hattori","year":"2016","unstructured":"Hattori N. Movement disorders: advances in 2015. Lancet Neurol. 2016;15:8\u20139.","journal-title":"Lancet Neurol"},{"key":"3578_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s12264-022-00829-6","volume":"38","author":"H Xu","year":"2022","unstructured":"Xu H, Cheng X, Song Q, Yang Y, Wang C, Kang X. Induced dopaminergic neurons for Parkinson\u2019s disease therapy: targeting the striatum or midbrain\/substantia Nigra pars compacta? Neurosci Bull. 2022;38:820\u20134.","journal-title":"Neurosci Bull"},{"issue":"Suppl 11","key":"3578_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J. Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):11\u20136.","journal-title":"Mov Disord"},{"issue":"Pt 11","key":"3578_CR4","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain. 2000;123(Pt 11):2297\u2013305.","journal-title":"Brain"},{"key":"3578_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448\u201358.","journal-title":"Mov Disord"},{"key":"3578_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10286-021-00801-w","volume":"31","author":"M Wang","year":"2021","unstructured":"Wang M, Wang W, Gao Z, et al. Dyskinesia-hyperpyrexia syndrome in Parkinson\u2019s disease: a systematic review. Clin Auton Res. 2021;31:529\u201342.","journal-title":"Clin Auton Res"},{"key":"3578_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol. 2015;132:96\u2013168.","journal-title":"Prog Neurobiol"},{"key":"3578_CR8","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"Group PDMC, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196\u2013205.","journal-title":"Lancet"},{"key":"3578_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.27352","volume":"33","author":"M Kasten","year":"2018","unstructured":"Kasten M, Hartmann C, Hampf J, et al. Genotype-phenotype relations for the Parkinson\u2019s disease genes parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord. 2018;33:730\u201341.","journal-title":"Mov Disord"},{"key":"3578_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","volume":"17","author":"SD Aradi","year":"2020","unstructured":"Aradi SD, Hauser RA. Medical management and prevention of motor complications in Parkinson\u2019s disease. Neurotherapeutics. 2020;17:1339\u201365.","journal-title":"Neurotherapeutics"},{"key":"3578_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mds.22519","volume":"25","author":"R Sakakibara","year":"2010","unstructured":"Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson\u2019s disease. Mov Disord. 2010;25:2\u201312.","journal-title":"Mov Disord"},{"key":"3578_CR12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3906\/sag-1507-148","volume":"46","author":"E Benli","year":"2016","unstructured":"Benli E, Ozer FF, Kaya Y, Ozcan TS, Ayyildiz A. Is there a difference between Parkinson disease patients and a control group in terms of urinary symptoms and quality of life? Turk J Med Sci. 2016;46:1665\u201371.","journal-title":"Turk J Med Sci"},{"key":"3578_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737\u201345.","journal-title":"Mov Disord"},{"key":"3578_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","volume":"35","author":"C McDonald","year":"2017","unstructured":"McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson\u2019s disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8\u201316.","journal-title":"Parkinsonism Relat Disord"},{"key":"3578_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.parkreldis.2003.07.001","volume":"10","author":"P Hobson","year":"2003","unstructured":"Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson\u2019s disease patients and normal controls. Parkinsonism Relat Disord. 2003;10:67\u201371.","journal-title":"Parkinsonism Relat Disord"},{"key":"3578_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0090-4295(76)90556-2","volume":"7","author":"GS Benson","year":"1976","unstructured":"Benson GS, Raezer DM, Anderson JR, Saunders CD, Corriere JN Jr. Effect of levodopa on urinary bladder. Urology. 1976;7:24\u20138.","journal-title":"Urology."},{"key":"3578_CR17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"3578_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mdc3.12636","volume":"5","author":"A Pavy-Le Traon","year":"2018","unstructured":"Pavy-Le Traon A, Cotterill N, Amarenco G, et al. Clinical rating scales for urinary symptoms in Parkinson disease: critique and recommendations. Mov Disord Clin Pract. 2018;5:479\u201391.","journal-title":"Mov Disord Clin Pract"},{"key":"3578_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/mds.10248","volume":"17","author":"C Ramaker","year":"2002","unstructured":"Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson\u2019s disease. Mov Disord. 2002;17:867\u201376.","journal-title":"Mov Disord"},{"key":"3578_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/mds.25070","volume":"27","author":"S Lessig","year":"2012","unstructured":"Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson\u2019s disease. Mov Disord. 2012;27:1125\u20138.","journal-title":"Mov Disord"},{"key":"3578_CR21","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21:916\u201323.","journal-title":"Mov Disord"},{"key":"3578_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40035-020-00223-0","volume":"9","author":"E Dinter","year":"2020","unstructured":"Dinter E, Saridaki T, Diederichs L, Reichmann H, Falkenburger BH. Parkinson\u2019s disease and translational research. Transl Neurodegener. 2020;9:43.","journal-title":"Transl Neurodegener"},{"key":"3578_CR23","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137:2731\u201342.","journal-title":"Brain"},{"key":"3578_CR24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord. 2013;28:1064\u201371.","journal-title":"Mov Disord"},{"key":"3578_CR25","doi-asserted-by":"crossref","unstructured":"Reichmann H, Lees A, Rocha JF, Magalhaes D, Soares-da-Silva P, investigators O. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:1-9.","DOI":"10.1186\/s40035-020-00187-1"},{"key":"3578_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.smrv.2010.02.004","volume":"15","author":"S Zoccolella","year":"2011","unstructured":"Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson\u2019s disease: the contribution of epidemiological studies. Sleep Med Rev. 2011;15:41\u201350.","journal-title":"Sleep Med Rev"},{"key":"3578_CR27","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","volume":"63","author":"RA Hauser","year":"2006","unstructured":"Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756\u201360.","journal-title":"Arch Neurol"},{"key":"3578_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41598-020-79110-7","volume":"11","author":"A Luca","year":"2021","unstructured":"Luca A, Monastero R, Baschi R, et al. Cognitive impairment and levodopa induced dyskinesia in Parkinson\u2019s disease: a longitudinal study from the PACOS cohort. Sci Rep. 2021;11:867.","journal-title":"Sci Rep"},{"key":"3578_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mds.21253","volume":"22","author":"K Winge","year":"2007","unstructured":"Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson\u2019s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22:220\u20135.","journal-title":"Mov Disord"},{"key":"3578_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.03.009","volume":"27","author":"AG Murchison","year":"2016","unstructured":"Murchison AG, Fletcher C, Cheeran B. Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson\u2019s disease on DBS (GPi). Parkinsonism Relat Disord. 2016;27:107\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"3578_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnsyn.2014.00022","volume":"6","author":"SA Lim","year":"2014","unstructured":"Lim SA, Kang UJ, McGehee DS. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci. 2014;6:22.","journal-title":"Front Synaptic Neurosci"},{"key":"3578_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.nbd.2013.10.016","volume":"62","author":"M Bourdenx","year":"2014","unstructured":"Bourdenx M, Nilsson A, Wadensten H, et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Neurobiol Dis. 2014;62:307\u201312.","journal-title":"Neurobiol Dis"},{"key":"3578_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrn2401","volume":"9","author":"CJ Fowler","year":"2008","unstructured":"Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9:453\u201366.","journal-title":"Nat Rev Neurosci"},{"key":"3578_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/nau.1930120302","volume":"12","author":"B Aranda","year":"1993","unstructured":"Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993;12:203\u20139.","journal-title":"Neurourol Urodyn"},{"key":"3578_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/mds.10403","volume":"18","author":"T Uchiyama","year":"2003","unstructured":"Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson\u2019s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18:573\u20138.","journal-title":"Mov Disord"},{"key":"3578_CR36","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/mds.22840","volume":"24","author":"T Uchiyama","year":"2009","unstructured":"Uchiyama T, Sakakibara R, Yamamoto T, et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson\u2019s disease. Mov Disord. 2009;24:2386\u201390.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03578-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T06:07:59Z","timestamp":1710223679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03578-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3578"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03578-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients\u2019 information was collocated from the LEAD-PD. All patients signed the informed consent before inclusion. The study was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests and approve the publication of the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}